AstraZeneca announces collaboration with Turbine

Turbine announced a collaboration with AstraZeneca (AZN) to test the ability of Turbine’s platform to rationalize antibody-drug conjugate discovery by predicting response mechanisms, informing ADC positioning, and reducing the need for large-scale cell line screens. This collaboration will apply Turbine’s platform, which virtualizes biological experiments at scale, to not only improve the efficiency and speed of ADC discovery but also deliver mechanistic insights that current experimental screening approaches may typically lack.